Abstracts tagged "TRACTISS"

Abstract Number: 0987 • ACR Convergence 2021
Rituximab Prevents the Progression of B-cell Driven Inflammatory Infiltrate in the Minor Salivary Glands of Primary Sjogren’s Syndrome by Downregulating Immunological Pathways Key in Ectopic Germinal Centre Organization: Results from the TRACTISS Trial
Elena Pontarini¹, Farzana Chowdhury¹, Elisabetta Sciacca¹, Sofia Grigoriadou¹, Felice Rivellese¹, Davide Lucchesi¹, Katriona Goldmann¹, Liliane Fossati-Jimack¹, Paul Emery², Wan-Fai NG³, Nurhan Sutcliffe⁴, Colin C Everett⁵, Catherine Fernandez⁵, Anwar Tappuni⁶, Myles Lewis¹, Costantino Pitzalis⁷, Simon J Bowman⁸ and Michele Bombardieri¹, ¹Queen Mary University of London, William Harvey Research Institute, London, United Kingdom, ²Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds and Leeds NIHR Biomedical Research Centre, Leeds, United Kingdom, ³Translational and Clinical Research Institute, Newcastle University,, Newcastle, United Kingdom, ⁴Royal London Hospital, Bart’s Health NHS Trust, London, United Kingdom, ⁵Leeds Institute for Clinical Trials Research, University of Leeds, Leeds, United Kingdom, ⁶Oral Immunobiology and Regenerative Medicine, Institute of Dentistry, Queen Mary University of London, London, United Kingdom, ⁷Queen Mary University of London, London, United Kingdom, ⁸Department of Rheumatology, University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom
Background/Purpose: The pathogenic role of B-cells in primary Sjögren’s Syndrome (pSS) is well established and B cell abnormalities are hallmarks of the disease. Because of…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].